Bispecific Products

Bispecific and multi-specific antibodies represent an emerging class of therapeutics. Unlike traditional antibodies, these are capable of binding to multiple distinct antigens simultaneously and may offer certain benefits such as improved response rates. Compugen licensed to AstraZeneca rights for the development of bispecific and multi-specific immuno-oncology antibody products derived from COM902 (anti-TIGIT antibody).